{
    "clinical_study": {
        "@rank": "20164", 
        "acronym": "PALG-AML2012", 
        "arm_group": [
            {
                "arm_group_label": "Induction, DAC", 
                "arm_group_type": "Other", 
                "description": "The first stage of treatment.\nFirst DAC induction cycle is common to all patients (regardless of risk group). After completion of induction I occurs early assessment of bone marrow on the +14 day after the start of treatment (+7 day after completion of chemotherapy)."
            }, 
            {
                "arm_group_label": "II early induction, CLAG", 
                "arm_group_type": "Other", 
                "description": "Patients with blasts in the bone marrow in D14> 10% receive early second induction (CLAG) which start form +16  day.\nPatients with blasts in the bone marrow in D14 \u2264 10% do not receive early second induction and are qualified to assess the response times on +28 day or after full  morphology recovery (if it occurs before the +28 day"
            }, 
            {
                "arm_group_label": "Consolidation, I HAM cycle", 
                "arm_group_type": "Other", 
                "description": "I induction cycle starts after complete remission (CR).\n- After I consolidation, patients from Intermediate I an Intermediate II group (ELN prognostic system):\nIf compatible donor is present  - allogeneic HSCT qualification after I or II consolidation. If compatible donor for allogeneic HSCT  is not present  - attempt to CD34+ mobilization for autologous SCT after II consolidation\n- After I consolidation, patients from Adverse risk group (ELN prognostic system):\nIf compatible donor is present  - immediate qualification for allogeneic HSCT.\n- Finding a donor should be initiated in all patients, at the latest after the end of I induction. In the first place, it should be checked whether the patient has a donor family, if not - searching start for an unrelated donor. For patients with no compatible donor for allogeneic HSCT - need to start searching for an alternative donor"
            }, 
            {
                "arm_group_label": "II Consolidation HiDAraC", 
                "arm_group_type": "Other", 
                "description": "Patients from all 5 risk group receive second after first consolidation [Ara-C] Patient from Very adverse risk receive Ara-C + CLA (Cladribine). If it is needed - more intensive consolidation treatment with 2-Cda.\nPatients form Very adverse risk receive Maintenance treatment:\nDecitabine 20 mg/m2 60 min infusion  iv (Intravenous injection) for 5 days every 6 weeks.\nPatients from Favorable, - Intermediate I an Intermediate II risk groups: CD34+ mobilization (HSCT qualification)."
            }, 
            {
                "arm_group_label": "Consolidation, III HiDAraC cycle", 
                "arm_group_type": "Other", 
                "description": "Patients from Favorable, Intermediate I an Intermediate II risk groups receive III consolidation or autologous HSCT (depends on results of mobilization).\nPatients from Adverse risk receive III Consolidation HiDAraC + Cladribina (CLA) If no CR: CLAG-M reinduction therapy and after CR - treatment according to protocol."
            }
        ], 
        "brief_summary": {
            "textblock": "In view of the diversity of the biology of acute myeloid leukemia (AML) therapy in\n      individual patients must be individualized. One of the tools for this is\n      molecular-cytogenetic stratification. It divides patients into five categories (prognostic\n      groups): Favorable, Intermediate-1, Intermediate-2, Adverse and Very adverse risk. After\n      remission proceedings are tailored depending on prognostic determined groups.\n\n      Research of PALG group in the application in the second line regimen CLAG and CLAG-M proved\n      high effectiveness of this treatment with low toxicity. Considering experience of PALG\n      groups, it seems that the use of the schema CLAG early as the second induction therapy is a\n      viable treatment option."
        }, 
        "brief_title": "Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (\u226460) With Acute Myeloid Leukemia", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with AML with one of 5 prognostic categories based on modified\n      cytogenetic-molecular stratification (European Leukemia Net Prognostic System - ENL)\n\n      Favorable risk\n\n      t(8;21)(q22;q22); RUNX1-RUNX1T1 inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Mutated\n      NPM1 without FLT3-ITD (NK) Mutated CEBPA (NK)\n\n      Intermediate I risk\n\n      Mutated NPM1 with FLT3-ITD (NK) Wild-type NPM1 and FLT3-ITD (NK) Wild-type NPM1 without\n      FLT3-ITD (NK)\n\n      Intermediate II risk\n\n      t(9;11)(p22;q22); MLLT3-MLL cytogenic abnormalities other than favorable or adverse\n\n      Adverse risk\n\n      Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN-EVI1\n\n      Very adverse risk monosomal karyotype (MK): -5 or del(5q); -7; abnl(17p); complex karyotype\n\n      Goals:\n\n        -  Evaluation of the impact of therapy tailored to the risk factors on outcome of AML\n           patients aged \u2264 60.\n\n        -  Evaluation of the possibility to improve the results of induction therapy through the\n           use of early 2nd induction in patients with persistent leukemic infiltration of the\n           bone marrow at the 14th day,\n\n        -  Evaluation of the impact of the minimal residual disease (MRD) presence assessed by\n           Immunophenotyping method,  on the results of treatment of AML patients aged \u2264 60,\n\n        -  Assessing the significance of monitoring the number of leukemic stem cells (LSC) in\n           bone marrow and peripheral  blood and their influence on clinical course and outcome of\n           AML treatment,\n\n        -  Assessment of the LSC determination usefulness in MRD monitoring in patients with AML,\n\n        -  Evaluation of the prognostic significance of the expression of CXCR-4 on the surface of\n           leukemic cells and their impact on the clinical course and outcome of AML - trying to\n           select a group of patients who potentially would benefit from the use of\n           chemosensitization with plerixafor,\n\n        -  Evaluation of autologous HSCT effectiveness in consolidation therapy in AML patients\n           from 3 following cytogenetic-molecular risk groups: Favorable, Intermediate I,\n           Intermediate II,\n\n        -  Comparison of the overall survive (OS) and leukemia-free survival after autologous and\n           allogeneic HSCT in AML patients from Intermediate I  and Intermediate II\n           cytogenetic-molecular risk groups (biological randomization donor vs. donor)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult acute myeloid leukemia\n\n          -  Age: \u226518  and \u2264 60\n\n          -  Clinical condition of the patient allows to carry out induction therapy: ECOG\n             performance status: \u2264 2 and the Hematopoietic Cell Transplant-Co-morbidity Index\n             (HCT-I): \u22643\n\n          -  Informed consent to participate in the study (ICF signed)\n\n          -  The second early induction start criteria is in addition to the listed above, the\n             percentage of the blasts on the level >10% on 7th day.\n\n        Exclusion Criteria:\n\n          -  No informed consent for participation in the study, mental illness, which don't allow\n             to obtain informed consent and conduct the treatment according to the protocol\n\n          -  Pregnancy\n\n          -  HIV infection\n\n          -  Active cancer\n\n          -  Active hepatitis virus infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072811", 
            "org_study_id": "PALG-AML2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Induction, DAC", 
                "description": "DNR 60 mg/m2 0,5h infusion iv  on 1-3 days\n2-CdA 5 mg/m2 2h. infusion iv  on 1-5 days\nAra-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days", 
                "intervention_name": "DAC", 
                "intervention_type": "Drug", 
                "other_name": [
                    "- Cladribine", 
                    "- Cytosine arabinoside [Ara-C]", 
                    "- Daunorubicin"
                ]
            }, 
            {
                "arm_group_label": "II early induction, CLAG", 
                "description": "G-CSF 30MU sc, on 0-5 days\nMitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days\nCladribine 5mg/m2 in 2h infusion iv, on 1-5 days\nAra-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day", 
                "intervention_name": "CLAG", 
                "intervention_type": "Drug", 
                "other_name": [
                    "- Granulocyte-colony stimulating factor [G-CSF]", 
                    "- Cladribine", 
                    "- Mitoxantrone", 
                    "- Cytosine arabinoside [Ara C]"
                ]
            }, 
            {
                "arm_group_label": "Consolidation, I HAM cycle", 
                "description": "Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days\nMitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days", 
                "intervention_name": "Consolidation, I HAM cycle", 
                "intervention_type": "Drug", 
                "other_name": [
                    "- Mitoxantrone", 
                    "- Cytosine arabinoside [Ara-C]"
                ]
            }, 
            {
                "arm_group_label": "II Consolidation HiDAraC", 
                "description": "\u2022\tAra-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)", 
                "intervention_name": "II Consolidation HiDAraC", 
                "intervention_type": "Drug", 
                "other_name": [
                    "- Cytosine arabinoside [Ara-C]", 
                    "- Cladribine"
                ]
            }, 
            {
                "arm_group_label": "Consolidation, III HiDAraC cycle", 
                "description": "Ara-C 3g/m2 every 12h; 3h infusion iv  on 1,3,5 days\n2-CdA 5 mg/m2 2h infusion iv  on 1,3,5 days, 2h before Ara-C", 
                "intervention_name": "Consolidation, III HiDAraC cycle", 
                "intervention_type": "Drug", 
                "other_name": [
                    "- Cytosine arabinoside [Ara-C]", 
                    "- 2-CdA [Cladribine, 2-Chlorodeoxyadenosine]"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Cladribine", 
                "Daunorubicin", 
                "Mitoxantrone", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "AML", 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lodz", 
                    "country": "Poland", 
                    "zip": "93-510"
                }, 
                "name": "Copernicus Memorial Hospital"
            }, 
            "investigator": {
                "last_name": "Agnieszka Wierzbowska, Dr hab. n. med.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "5", 
        "official_title": "Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells", 
        "overall_contact": {
            "email": "agawierzbowska@wp.pl", 
            "last_name": "Agnieszka Wierzbowska, dr hab.n.med.", 
            "phone": "+48426895191"
        }, 
        "overall_contact_backup": {
            "email": "agnieszka.pluta@op.pl", 
            "last_name": "Agnieszka Pluta, dr n.med.", 
            "phone": "+48426895191"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Poland: Ministry of Health", 
                "Poland: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Outcome measure after induction:\nAt +28 day after treatment or after full morphology recovery (if it occurs before the +28 day)\nComplete remission, according to Cheson's CR criteria:\nLack of extramedullary infiltration,\nPlatelet count> 100 G / L,\nNeutrophil count> 1.0 G / L,\nLack of blast cells in the blood,\nBone marrow blasts <5% in the cytomorphology.\nAfter induction treatment, patients are qualified for one of the pro-remission treatment options, which is associated with cytogenetic-molecular risk  groups, according to the modification of the molecular ELN / MDACC.\nTherapeutic decisions are being made according to cytogenetic-molecular stratification: Favorable, Intermediate-1, Intermediate-2, Adverse and Very adverse risk.", 
            "measure": "Complete remission after induction", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072811"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Polish Adult Leukemia Group", 
            "investigator_full_name": "dr hab. n. med. Agnieszka Wierzbowska", 
            "investigator_title": "PhD in Copernicus Memorial Hospital, Hematology Department", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Polish Adult Leukemia Group", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Polish Adult Leukemia Group, Gliwice, Poland", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Copernicus Memorial Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "dr hab. n. med. Agnieszka Wierzbowska", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}